Atai Life Sciences N.V. (ATAI)

This week, 4 Diversified Consumer Services stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

4 Diversified Consumer Services Stocks to Sell Now

By Portfolio Grader Dec 21, 2016

This week, 4 Diversified Consumer Services stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

3 Diversified Consumer Services Stocks to Buy Now

By Portfolio Grader Aug 31, 2016

3 Diversified Consumer Services stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").

3 Diversified Consumer Services Stocks to Buy Now

By Portfolio Grader Aug 3, 2016

This week, 3 Diversified Consumer Services stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").

5 Best Stocks Under $5 This Week

By Ethan Roberts, InvestorPlace Contributor Sep 25, 2015

Markets were lackluster this week, but ATA, Jaguar Animal Health, Biocept, Aware and CVSL were all tigers.

Psychedelic stocks gain after FDA priority review for MDMA therapy (NYSE:CYBN)

From Seeking Alpha Feb 12, 2024

The FDA priority review for an MDMA-linked therapy leads to a surge in shares of psychedelic medicine companies such as Mind Medicine (MNMD). Read more here.

Atai Life Sciences names Anne Johnson as its CFO (NASDAQ:ATAI)

From Seeking Alpha Feb 6, 2024

Atai Life Sciences appoints Anne Johnson as CFO, succeeding Stephen Bardin.

3 Big New Catalysts for Psychedelics Stocks in 2024

From The Motley Fool Jan 8, 2024

This could be the year that psychedelics stocks start to fly.

Atai buys 35.5% stake in psychedelic drug developer, stock rallies 18% (NASDAQ:ATAI)

From Seeking Alpha Jan 4, 2024

Shares of Atai Life Sciences surged 18% on news the company has bought a 35.5% stake in psychedelic drug developer Beckley Psytech. Read more here.

Thiel-Backed Psychedelic Firm Atai to Buy Stake in Beckley

From Bloomberg Jan 4, 2024

Atai Life Sciences NV is close to acquiring a stake in smaller rival Beckley Psytech to expand its portfolio of drug candidates for the treatment of mental diseases, people familiar with the matter said.

Why Shares of Atai Life Sciences Rose Friday

From The Motley Fool Mar 31, 2023

The company's co-founder and chairman increased his position and explained why.

Atai Life Sciences N.V. (ATAI)

ATAI Stock Earnings: ATAI Life Sciences Beats EPS, Misses Revenue for Q4 2023

Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution

3 Penny Stocks to Make You the Millionaire Next Door

Atai Layoffs 2023: What to Know About the Latest ATAI Job Cuts

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Atai Life Sciences N.V. (ATAI)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

ATAI Stock Predictions, Articles, and Atai Life Sciences N.V. News

Subscriber Sign in